Skip to main content
Orexo logo

Orexo — Investor Relations & Filings

Ticker · ORX ISIN · SE0000736415 LEI · 549300LJ5CCWDPTK9Z08 ST Manufacturing
Open in API
Filings indexed 843 across all filing types
Latest filing 2022-10-11 Earnings Release
Country SE Sweden
Listing ST ORX

About Orexo

https://orexo.com/

Orexo is a commercial-stage pharmaceutical company focused on developing improved pharmaceuticals and digital therapies. The company addresses unmet patient needs, particularly within substance use disorders and mental health. It leverages proprietary drug delivery and formulation technologies to create innovative treatment solutions. Orexo's activities span research, development, and commercialization of its products.

Recent filings

Filing Released Lang Actions
Orexo announces positive data from phase 1 clinical study for OX640 - a nasal epinephrine rescue medication for allergic reactions
Earnings Release Classification · 1% confidence The document is explicitly titled "Press Release" and announces positive clinical trial data for a drug candidate (OX640), including key results, market context, and future partnership strategies. It is dated October 11, 2022, and concludes with a statement indicating it contains information Orexo AB is obliged to make public pursuant to the EU Market Abuse Regulation. This format—a brief, timely announcement of material, non-financial or preliminary financial news—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a full financial report (like 10-K or IR) and focuses on operational/clinical progress rather than just financial figures, it fits best as an Earnings Release (ER) if it were quarterly results, but since it's clinical trial data, it functions as a major operational update. Given the options, and recognizing that press releases announcing significant operational milestones often overlap with the function of an ER (announcing key performance indicators/updates), or are simply general regulatory disclosures, I must choose the most fitting category. It is not a Call Transcript (CT), Investor Presentation (IP), or a formal financial report (10-K, IR). Because it is a formal announcement of material information required to be made public, and it is not a specific filing like DIRS or DIV, it falls under the general category of a significant regulatory disclosure. However, in many databases, press releases announcing key operational milestones (like positive Phase 1 data) are often categorized as Earnings Releases (ER) if they impact the company's outlook, or sometimes as Regulatory Filings (RNS). Given the content is a major operational update, ER is plausible, but RNS is the safest fallback for non-standard regulatory announcements. Since it is a 'Press Release' announcing material news, and it doesn't fit the specific financial report types, RNS (Regulatory Filings/General Announcement) is the most appropriate general classification for this type of disclosure that isn't a specific financial report or management disclosure. FY 2022
2022-10-11 English
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 1% confidence The document is a 'Delårsrapport' (Interim Report) for the second quarter of 2022 for the company Orexo. It contains comprehensive financial statements, including income statements, cash flow data, and key performance indicators (EBITDA, net sales, earnings per share) for the specified period. It also includes management commentary, business updates, and forward-looking statements. It is not an announcement of a report (RPA) because it contains the actual financial data and analysis, nor is it a full annual report (10-K). Therefore, it is classified as an Interim/Quarterly Report. Q2 2022
2022-07-14 Swedish
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Q2 Interim Report 2022' and contains comprehensive financial statements, including income statements, balance sheet data, and management commentary for the second quarter of 2022. It provides detailed financial performance metrics, business updates, and outlook, which aligns perfectly with the definition of an Interim/Quarterly Report (IR). Q2 2022
2022-07-14 English
Orexos digitala terapi deprexis® subventionerad av amerikanska Veterans Affairs Federal Supply Schedule
Regulatory Filings Classification · 1% confidence The document is titled "Pressmeddelande" (Press Release) and announces a significant business development: Orexo being awarded a ten-year contract with the US Veterans Affairs Federal Supply Schedule (VA FFS) for the subsidization of their digital therapy, deprexis®. This is a material, non-financial announcement regarding a major commercial agreement and market access achievement. It is not a full financial report (10-K or IR), an earnings release (ER), a management discussion (MDA), or a proxy statement. Since it is a specific, material announcement that doesn't fit the other specific categories (like M&A, Capital Change, Dividend), it falls best under the general regulatory announcement category, RNS (Regulatory Filings), as it is a public disclosure of material information required under market regulations (mentioned at the end: "Denna information är sådan information som Orexo AB (publ) är skyldigt att offentliggöra enligt EU:s marknadsmissbruksförordning").
2022-07-13 Swedish
Orexo's digital therapy deprexis® reimbursed under the US Veterans Affairs Federal Supply Schedule
Regulatory Filings Classification · 1% confidence The document is explicitly labeled as a "Press release" and announces a significant business development: Orexo securing a Federal Supply Schedule contract with the US Veterans Affairs (VA) for its digital therapy, deprexis®. This type of announcement, detailing a major commercial agreement, reimbursement status, and future access plans, is characteristic of a general corporate update or news release. It is not a formal regulatory filing like a 10-K, an earnings release (ER) which focuses on financial figures, or a specific report like an Audit Report (AR) or Interim Report (IR). Since it is a general corporate announcement that doesn't fit the highly specific categories (like DIRS, DIV, CAP, etc.), the most appropriate classification is the general regulatory/corporate announcement fallback, RNS (Regulatory Filings), as it serves as a public disclosure of material information.
2022-07-13 English
Interim / Quarterly Report 2022
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Delårsrapport Kv 1 2022' (Interim Report Q1 2022) and contains comprehensive financial statements, management commentary, and operational updates for the first quarter of 2022. It is a substantive financial report rather than a mere announcement or certification, fitting the definition of an Interim/Quarterly Report (IR). Q1 2022
2022-04-28 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.